Placebo ZNS — Competitive Intelligence Brief

Placebo ZNS (Placebo ZNS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant / Antiepileptic agent. Area: Neurology.

phase 3 Anticonvulsant / Antiepileptic agent Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase Neurology Small molecule

Target snapshot

Placebo ZNS (Placebo ZNS) — Impax Laboratories, LLC. Zonisamide is a sulfonamide anticonvulsant that reduces neuronal excitability through multiple mechanisms including sodium and calcium channel blockade.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo ZNS TARGET	Placebo ZNS	Impax Laboratories, LLC	phase 3	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase
Adjunctive Zonisamide	Adjunctive Zonisamide	Eisai Inc.	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase
Oral Zonisamide Therapy	Oral Zonisamide Therapy	Affiliated Hospital of Nantong University	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase
Low dose zonisamide	Low dose zonisamide	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase
carbamazepine oxcarbazepine	carbamazepine oxcarbazepine	Odense University Hospital	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels
Topiramate-Implant	Topiramate-Implant	University of Sao Paulo	marketed	Anticonvulsant / Antiepileptic agent	GABA-A receptor, sodium channels, glutamate receptors
Topiramate Standard	Topiramate Standard	Janssen Korea, Ltd., Korea	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant / Antiepileptic agent class)

1. University of Sao Paulo · 2 drugs in this class
2. Mario Negri Institute for Pharmacological Research · 2 drugs in this class
3. Janssen Korea, Ltd., Korea · 1 drug in this class
4. Johnson & Johnson Taiwan Ltd · 1 drug in this class
5. Ministry of Health and Sports, Myanmar · 1 drug in this class
6. Odense University Hospital · 1 drug in this class
7. UCB BIOSCIENCES GmbH · 1 drug in this class
8. University Hospitals Cleveland Medical Center · 1 drug in this class
9. Eisai Korea Inc. · 1 drug in this class
10. Upsher-Smith Laboratories · 1 drug in this class